I think it might be the size of the glaucoma market and the strength of these rabbit tests....NEMUS plans to continue development of NB1111, our proprietary ocular prodrug of THC for the treatment and management of glaucoma, which is an estimated $8 billion global market with an urgent medical need for therapies with new mechanisms of action. Multiple testing in the rabbit glaucoma model by the University of Mississippi demonstrated a 45% reduction in elevated intra-ocular pressure (IOP) and the ability of the drug to reach all compartments of the eye. Based on the evolving shift of drug delivery to enhance compliance in eye diseases, particularly glaucoma, the company will be looking to administer the drug via an implantable sustained release technology. Studies have shown (Am J Ophthal, 2007; 144(4):533-40) that poor topical drop compliance is a significant factor in the progression of glaucoma to blindness. In addition to improving therapy adherence, this type of drug delivery has the potential to reduce side effects associated with drops, lower complication rates of the disease that result in cost-effective care –leading to improved clinical outcomes. NEMUS plans on advancing testing of NB1111 into a second animal model in the first quarter of 2016 and hold a pre-Investigational New Drug (IND) meeting with the FDA in the first half of 2016. The company has been approached by a number of manufacturers of sustained delivery devices and anticipates identifying a compatible technology in 2016.
News 
Market Data 
Discover 
